期刊
CELL METABOLISM
卷 30, 期 6, 页码 1075-+出版社
CELL PRESS
DOI: 10.1016/j.cmet.2019.11.011
关键词
-
资金
- IMBIO-DC
- ONE Study [FP7-260687]
- BIODRIM [FP7-305147]
- IHU-CESTI [ANR-10-IBHU-005]
- ANR Jeunes Chercheurs [ANR-16-CE18-0001-01]
- DHU Oncogreffe
- LabexIGO [ANR-11-LABX-0016-01]
- EU COST actions [BM1305, BM1404]
- Agence Nationale de la Recherche (ANR) [ANR-16-CE18-0001] Funding Source: Agence Nationale de la Recherche (ANR)
Cell therapy is a promising strategy for treating patients suffering from autoimmune or inflammatory diseases or receiving a transplant. Based on our preclinical studies, we have generated human autologous tolerogenic dendritic cells (ATDCs), which are being tested in a first-in-man clinical trial in kidney transplant recipients. Here, we report that ATDCs represent a unique subset of monocyte-derived cells based on phenotypic, transcriptomic, and metabolic analyses. ATDCs are characterized by their suppression of T cell proliferation and their expansion of Tregs through secreted factors. ATDCs produce high levels of lactate that shape T cell responses toward tolerance. Indeed, T cells take up ATDC-secreted lactate, leading to a decrease of their glycolysis. In vivo, ATDCs promote elevated levels of circulating lactate and delay graft-versus-host disease by reducing T cell proliferative capacity. The suppression of T cell immunity through lactate production by ATDCs is a novel mechanism that distinguishes ATDCs from other cell-based immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据